N-Methylvalinol | 78617-54-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Methylvalinol
• 英文别名: 3-methyl-2-methylamino-butan-1-ol；3-Methyl-2-(methylamino)-1-butanol；3-methyl-2-(methylamino)butan-1-ol
• CAS: 78617-54-6
• 化学式: C₆H₁₅NO
• 分子量: 117.191
• InChiKey: VUJGKDVZMCDYDE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-Methylvalinol 、 5-Butyl-2,2-dichloro-4-(trimethylsilyl)-3(2H)-furanone 以 乙醚 为溶剂， 反应 18.0h， 以91%的产率得到
  参考文献：
  名称：

  Preparation of 2,2-Dichloro-3(2H)-furanone and Its Reactions with Heteronucleophiles

  摘要：

  DOI：

  10.1021/jo00104a058
• 作为产物：
  描述：

  N-甲基缬氨酸 在 四氢呋喃 、 lithium aluminium tetrahydride 作用下， 生成 N-Methylvalinol
  参考文献：
  名称：

  放线菌的代谢产物。第十五次沟通。棘皮霉素的组成†

  摘要：

  对于先前的2）3）分离的抗生素棘球霉素，根据已知的和新的分析数据以及降解结果，得出了新的化学式C 50 H 60 O 12 N 12 S 2。该式对应于不寻常的结构XIII，即具有由二噻吩环桥接的26个环成员的环八肽-二内酯。

  DOI：

  10.1002/hlca.19590420127

文献信息

• Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR)
  申请人：ZENTARIS AG

  公开号：US20030232873A1

  公开（公告）日：2003-12-18

  This invention provides new tetrahydrocarbazole derivatives that act as ligands for G-protein-coupled receptors (GPCR), especially as antagonists of the gonadotropin-releasing hormone (GnRH). A pharmaceutical composition that contains these new tetrahydrocarbazole derivatives as well as a process for the production of the new tetrahydrocarbazole derivatives are also provided. Moreover, this invention relates to the administration of tetrahydrocarbazole derivatives for treating pathologic conditions that are mediated by GPCR, especially for inhibiting GnRH, in mammals, especially humans, who require such an administration, as well as the use of tetrahydrocarbazole derivatives for the production of a pharmaceutical agent for treating GPCR-mediated pathologic conditions, especially for inhibiting GnRH.

  这项发明提供了作为G蛋白偶联受体（GPCR）配体的新四氢咔唑衍生物，特别是作为促性腺激素释放激素（GnRH）的拮抗剂。还提供了一种含有这些新四氢咔唑衍生物的药物组合物，以及一种生产这些新四氢咔唑衍生物的方法。此外，这项发明涉及给哺乳动物，特别是人类，需要这种给药的通过四氢咔唑衍生物治疗GPCR介导的病理状况，特别是抑制GnRH的治疗，以及利用四氢咔唑衍生物生产用于治疗GPCR介导的病理状况，特别是抑制GnRH的药物的用途。
• DERIVATIVES OF AMINOALKANOLS, METHOD OF OBTAINING OF AMINOALKANOLS AND THEIR USE
  申请人：Marona Henryk

  公开号：US20110028562A1

  公开（公告）日：2011-02-03

  The subject of the invention is a group of new derivatives of aminoalkaπols, more specifically [(phenoxy)alkyl]aminoalkanols and [(phenoxy)acyl)aminoalkanols, their method of obtaining and their use for production of a medicine which is used in the prophylaxis, prevention and/or treatment of diseases or symptoms having neurological background and for production of a medicine with anticonvulsant activity, which is used in seizures of various origin, also in the limbic system, in myoclonic or sound-induced seizures, in psychomotor epilepsy, as well as in relieving neuropathic or inflammatory pain.

  本发明涉及一组新的氨基烷醇衍生物，更具体地是[(苯氧基)烷基]氨基烷醇和[(苯氧基)酰基)氨基烷醇，它们的获取方法以及它们用于生产用于预防、预防和/或治疗具有神经学背景的疾病或症状的药物，以及用于生产具有抗惊厥活性的药物，用于各种起源的癫痫发作，也用于边缘系统、肌阵挛或声音诱发的癫痫发作、精神运动性癫痫，以及缓解神经病性或炎症性疼痛。
• PYRIMIDINE COMPOUND
  申请人：Matsushima Yuji

  公开号：US20110053912A1

  公开（公告）日：2011-03-03

  A novel and excellent method for preventing and/or treating diseases related to a cannabinoid type 2 receptor, based on an agonistic action on a cannabinoid type 2 receptor. It was found that a hetero ring derivative mainly having two substituents, for example, a pyrimidine-5-carboxamide derivative having a substituent amino group at the 2-position, exhibits a potent agonistic action on a cannabinoid type 2 receptor, and can be an agent for preventing and/or treating diseases related to a cannabinoid type 2 receptor such as inflammatory diseases, pain, and the like.

  一种预防和/或治疗与大麻素2型受体相关疾病的新颖优秀方法，基于对大麻素2型受体的激动作用。发现一种异核环衍生物主要具有两个取代基，例如，在2-位置具有取代基氨基的嘧啶-5-羧酰胺衍生物，表现出对大麻素2型受体的强效激动作用，可以成为预防和/或治疗与大麻素2型受体相关疾病，如炎症性疾病、疼痛等的药物。
• Imidazo and thiazolopyridines as jak3 kinase inhibitors
  申请人：Hemmerling Martin

  公开号：US20060287355A1

  公开（公告）日：2006-12-21

  The present invention relates to novel imidazo and thiazolopyridine compounds which are kinase inhibitors, methods for their preparation intermediates and pharmaceutical compositions comprising them. Formula (I)

  本发明涉及一种新型的咪唑和噻唑吡啶化合物，它们是激酶抑制剂，包括它们的制备方法、中间体和制药组合物。公式（I）
• C-PHENYL GLYCITOL COMPOUND
  申请人：Kakinuma Hiroyuki

  公开号：US20100022460A1

  公开（公告）日：2010-01-28

  Provided is a novel C-phenyl glycitol compound that may serve as a prophylactic or therapeutic agent for diabetes by inhibiting both SGLT1 activity and SGLT2 activity, thereby exhibiting a glucose absorption suppression action and a urine glucose excretion action. A C-phenyl glycitol compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof or a hydrate thereof wherein R 1 and R 2 are the same or different and represent a hydrogen atom, a hydroxyl group, a C 1-6 alkyl group, a C 1-6 alkoxy group or a halogen atom, R 3 is a hydrogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group or a halogen atom, Y is a C 1-6 alkylene group, —O—(CH 2 )n— (n is an integer of 1 to 4) or a C 2-6 alkenylene group, provided that when Z is —NHC(═NH)NH 2 or —NHCON(R B )R C , n is not 1, Z is —CONHR A , —NHC(═NH)NH 2 or —NHCON(R B )R C ,

  提供的是一种新型C-苯基甘露醇化合物，可以作为预防或治疗糖尿病的药物，通过抑制SGLT1活性和SGLT2活性，从而表现出抑制葡萄糖吸收和尿液葡萄糖排泄的作用。该化合物表示为以下式子（I）的C-苯基甘露醇化合物，或其药学上可接受的盐或水合物，其中R1和R2相同或不同，表示氢原子、羟基、C1-6烷基、C1-6烷氧基或卤素原子，R3表示氢原子、C1-6烷基、C1-6烷氧基或卤素原子，Y表示C1-6烷基、-O-(CH2)n-（n为1至4的整数）或C2-6烯基烷基，但当Z为-NHC（=NH）NH2或-NHCON（RB）RC时，n不为1，Z为CONHRA，-NHC（=NH）NH2或-NHCON（RB）RC。